VivoSim Labs, INC. SEC filings VIVS
VivoSim Labs, INC. has 819 filings in SEC EDGAR's recent list, going back to Aug 4, 2010. Its latest annual report, Form ARS, was filed on Aug 21, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (material agreement). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRER14A | Filing | Aug 13, 2026 | — |
| EFFECT | Filing | Aug 10, 2026 | — |
| NT 10-K | Filing | Jun 29, 2026 | Mar 31, 2026 |
| EFFECT | Filing | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 30, 2026 | — |
| CORRESP | Letter to the SEC | Mar 30, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2026 | — |
| DRS | Filing | Mar 9, 2026 | — |
| RW | Withdrawal request | Sep 26, 2025 | — |
| NT 10-Q | Filing | Feb 14, 2025 | Dec 31, 2024 |
| EFFECT | Filing | May 8, 2024 | — |
| CORRESP | Letter to the SEC | May 3, 2024 | — |
| CORRESP | Letter to the SEC | May 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2024 | — |
| EFFECT | Filing | Feb 8, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2024 | — |
| NT 10-K | Filing | Jun 29, 2023 | Mar 31, 2023 |
| DEFR14A | Filing | Sep 22, 2022 | — |
| EFFECT | Filing | Jan 29, 2021 | — |
| CORRESP | Letter to the SEC | Jan 27, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2021 | — |
| 425 | 8-k | Apr 8, 2020 | — |
| 425 | Filing | Apr 1, 2020 | — |
| 425 | Filing | Apr 1, 2020 | — |
| 425 | 8-k | Apr 1, 2020 | — |
| 425 | 8-k | Mar 27, 2020 | — |
| 425 | Filing | Mar 20, 2020 | — |
| 425 | 8-k | Mar 20, 2020 | — |
| 425 | Filing | Mar 16, 2020 | — |
| 425 | Filing | Mar 16, 2020 | — |
| CT ORDER | Filing | Mar 13, 2020 | — |
| SEC STAFF LETTER | Filing | Mar 3, 2020 | — |
| PX14A6G | Filing | Mar 3, 2020 | — |
| 425 | Filing | Mar 3, 2020 | — |
| 425 | Filing | Feb 26, 2020 | — |
| 425 | Filing | Feb 26, 2020 | — |
| EFFECT | Filing | Feb 24, 2020 | — |
| CORRESP | Letter to the SEC | Feb 20, 2020 | — |
| CORRESP | Letter to the SEC | Feb 13, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2020 | — |
| CORRESP | Letter to the SEC | Jan 29, 2020 | — |
| 425 | 8-k | Jan 29, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 21, 2020 | — |
| PX14A6G | Filing | Jan 21, 2020 | — |
| SEC STAFF LETTER | Filing | Jan 9, 2020 | — |
| 425 | 8-k | Dec 30, 2019 | — |
| 425 | 8-k | Dec 16, 2019 | — |
| CT ORDER | Filing | May 17, 2018 | — |
| EFFECT | Filing | Mar 23, 2018 | — |
| EFFECT | Filing | Feb 22, 2018 | — |
| CORRESP | Letter to the SEC | Feb 20, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 16, 2018 | — |
| CERTNAS | Auto-generated paper document | Aug 8, 2016 | — |
| 25 | Form 25 | Aug 5, 2016 | — |
| EFFECT | Filing | Jul 27, 2016 | — |
| 8-A12B | Form 8-a12b | Jul 26, 2016 | — |
| CT ORDER | Filing | Aug 5, 2015 | — |
| CT ORDER | Filing | Jun 9, 2015 | — |
| EFFECT | Filing | Mar 17, 2015 | — |
| CT ORDER | Filing | Jun 12, 2014 | — |
| EFFECT | Filing | Jul 26, 2013 | — |
| CERTNYS | Auto-generated paper document | Jul 9, 2013 | — |
| 8-A12B | Form 8-a12b | Jul 9, 2013 | — |
| EFFECT | Filing | Apr 4, 2013 | — |
| D | Filing | Jan 4, 2013 | — |
| SC TO-I/A | Amendment no. 4 to schedule to | Dec 28, 2012 | — |
| SC TO-I/A | Amendment no. 3 to schedule to | Dec 17, 2012 | — |
| SC TO-I/A | Amendment no. 2 to schedule to | Dec 5, 2012 | — |
| CORRESP | Letter to the SEC | Dec 4, 2012 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2012 | — |
| SC TO-I/A | Amendment no. 1 to schedule to | Nov 23, 2012 | — |
| SC TO-I | Schedule to | Nov 16, 2012 | — |
| EFFECT | Filing | Jul 6, 2012 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2012 | — |
| CT ORDER | Filing | Jun 21, 2012 | — |
| CT ORDER | Filing | Jun 21, 2012 | — |
| CORRESP | Letter to the SEC | May 10, 2012 | — |
| UPLOAD | Letter from the SEC | Apr 18, 2012 | — |
| CORRESP | Letter to the SEC | Mar 30, 2012 | — |
| CORRESP | Letter to the SEC | Mar 27, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2012 | — |
| 8-A12G | Form 8a | Mar 13, 2012 | — |
| D/A | Filing | Feb 29, 2012 | — |
| D | Filing | Feb 7, 2012 | — |
| NT 10-K | Annual report extension | Sep 28, 2011 | Jun 30, 2011 |
| EFFECT | Filing | May 13, 2011 | — |
| CORRESP | Letter to the SEC | May 11, 2011 | — |
| CORRESP | Letter to the SEC | May 6, 2011 | — |
| UPLOAD | Letter from the SEC | May 5, 2011 | — |
| CORRESP | Letter to the SEC | May 2, 2011 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2011 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2011 | — |
| CORRESP | Letter to the SEC | Apr 7, 2011 | — |
| CORRESP | Letter to the SEC | Mar 16, 2011 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2011 | — |
| CORRESP | Letter to the SEC | Feb 4, 2011 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2011 | — |
| CORRESP | Letter to the SEC | Dec 7, 2010 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2010 | — |
| D | Filing | Aug 4, 2010 | — |
Showing 105 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIVS (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1497253
- Former names
- ORGANOVO HOLDINGS, INC. (until Apr 23, 2025); REAL ESTATE RESTORATION & RENTAL, INC. (until Oct 31, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.